{'fraction_non_alphanumeric': 0.02787769784172662, 'fraction_numerical': 0.007194244604316547, 'mean_word_length': 5.217877094972067, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Use of Implanted Insulin Pumps to Treat IDDM

It is clear from morbidity, mortality and cost that our current treatment of insulin-dependent diabetes mellitus (IDDM) is inadequate. There are mounting data, furthermore, that while the correlation is not necessarily simple and direct, there is a relationship between glycemic control and complications. These considerations have stimulated research into new ways to treat IDDM, implanted insulin pumps being one new direction. Over more than 20 years, they have moved from small trials of constant rate pumps to long-term experience ( > 5 years) with variable rate, remotely controlled implanted insulin pumps. Currently, two pumps are in clinical trials, totaling well over 250 subjects. Intraperitoneal catheter block is the major adverse event, occurring at a rate of approximately 0.2 per patient-year. Further clinical trials leading to availability of the devices as approved medical therapy should occur in the next few years; incremental improvements will occur; but the fully implanted closed loop (sensor-driven) pump remains in the more distant future.